Survival outcomes by molecular subtypes based on receptor status in medullary breast carcinoma: a SEER database analysis
database[Title] 2026-04-19
Summary:
CONCLUSIONS: Despite presenting with more aggressive clinicopathological characteristics, MBC patients had a more favorable prognosis compared to those with IBC-NST. Molecular subtype was not associated with significant survival differences in MBC. Key determinants of survival in MBC included age, T stage, N stage, and chemotherapy.